What the evidence supports
Read this one once the others have done their work. It says plainly what the evidence supports and where it ends.
What the study supports. In a 12-week, single-blind, vehicle-controlled trichoscopy study of 40 participants, hair density in the group using the active was 33.5% above baseline (p < 0.0001), against 7.2% in the vehicle group. Shaft diameter, the anagen-to-telogen ratio and scalp barrier measures moved the same way. Note 09 has the full design and its limits.
Who it was measured in. 40 women with diffuse thinning. The study does not speak to men, to patterned loss or to any other form of hair loss, and we will not suggest it does. If your situation is different from that cohort, the study tells you less.
What it does not support. 40 people over 12 weeks is a defined measurement, not a population claim. The figure is a group average; individual results ranged from no change to a large change. The record ends at week 12. It is not a promise about you, and we make none.
Where the Scalp Reset Serum stands. It is a cosmetic scalp treatment whose job is preparation: it lifts buildup and excess oil and rebalances the scalp surface. The measured figure belongs to the active and we do not extend it.
How to decide. If you have diffuse thinning and 12 weeks to commit, that is the case the evidence was built on. If your situation is patterned loss or long-bare areas, a dermatologist is the right first call. The results guarantee on the Advanced Protocol exists because we will not predict your result: two photographs, 12 weeks apart, and if we cannot see a difference, we refund the product price. Note 18 has the method.
OF·27 is a cosmetic. It is not intended to diagnose, treat, cure or prevent any disease.
What does the cited evidence support?
In a twelve-week, single-blind, vehicle-controlled study of forty women with telogen effluvium, hair density in the group applying the oleosome-fusion FGF·2 active was 33.5% above baseline (p<0.0001), against 7.2% for the vehicle. It is a group mean on an ingredient, not a study of the finished OF·27 formula and not a prediction for any individual.
Who was the active studied in?
Forty women with telogen effluvium, a diffuse, temporary form of shedding. Men, patterned loss and other forms of hair loss were not studied.
The notes, by email.
One note at a time, in reading order, and a message when a new one is published.
An independent hair-science program.
The protocol the notes describe: The OF·27 Protocol
OF·27 is marketed as a cosmetic and is not intended to diagnose, treat, cure or prevent any disease.